跳至主要内容
临床试验/NCT01737333
NCT01737333已完成不适用

A Multicenter, Multinational, Randomized Study of Standard vs. Patient-Adapted Protocols in Multidetector Computed Tomography (MDCT) of the Chest, Abdomen, Liver or Aorta

Bracco Diagnostics, Inc2 个研究点 分布在 2 个国家目标入组 1,493 人开始时间: 2012年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,493
试验地点
2
主要终点
Diagnostic Quality

研究概览

简要总结

Collection of data from different sites regardless of whether they use standard or tailored protocols for the application of high concentration iodinated contrast agents to assess if the individually patient-adapted protocols result in a similar diagnostic image quality.

详细描述

To record technical information and compare image quality regarding routine MDCT procedures with contrast administration using a tailored contrast injection and radiation dose protocol. The hypotheses are that the tailored protocols lead to a lower applied mean radiation dose compared to the use of standard protocols and will provide a more standardized contrast dose per patient size without impairing diagnostic quality.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •At least 18 years of age
  • •Scheduled to undergo contrast enhanced MDCT of the abdomen, liver, aorta, or chest
  • •Provides written informed consent

排除标准

  • •Previously enrolled and completed the study
  • •Known allergy to iodinated contrast media
  • •Pregnancy or lactation
  • •Clinically unsuitable for the study

结局指标

主要结局

Diagnostic Quality

时间窗: Immediately after the single injection of contrast agent

Images are to be assessed according to the following scale: 0=Uninterpretable (Image quality severely affected by motion artifacts or technical reasons; need to repeat the examination); 1=Insufficient (Impaired image quality precludes adequate diagnostic assessment because of severe image noise or insufficient contrast enhancement; need to repeat the examination); 2=Adequate (Image quality in terms of noise and contrast enhancement does not interfere with sufficient diagnostic assessment; delineation of small structures may be suboptimal); or 3=Good (Absent or minimal image noise and good contrast enhancement allow adequate diagnostic assessment with clear delineation of even small structures).

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

进行中(未招募)
不适用
Estudio Multinacional, Multicéntrico, Randomizado, Doble Ciego, para comparar la eficacia y seguridad de AVE5026 frente a enoxaparina en la Prevención de Tromboembolismo Venoso en Pacientes sometidos a Cirugía de Fractura de Cadera - SAVE-HIP2Profilaxis de Tromboembolismo Venoso en pacientes sometidos a Cirugía de Fractura de Cadera.MedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxis
EUCTR2007-007945-11-ESsanofi-aventis recherche & développement1,000
进行中(未招募)
不适用
Estudio Multinacional, Multicéntrico, Randomizado, Doble Ciego, para comparar la eficacia y seguridad de AVE5026 frente a enoxaparina en la Prevención de Tromboembolismo Venoso en Pacientes sometidos a Cirugía Electiva de Sustitución Total de Cadera. - SAVE-HIP1Profilaxis de episodio de Tromboembolismo Venoso en pacientes sometidos a Cirugía Electiva de Sustitución Total de Cadera.MedDRA version: 9.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxis
EUCTR2007-007944-80-ESsanofi-aventis recherche & développement2,320
进行中(未招募)
1 期
Estudio multinacional, multicéntrico, randomizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la seguridad, tolerabilidad y eficacia de la administración oral de laquinimod 0,6mg una vez al día en pacientes con esclerosis múltiple remitente recurrente (RRMS). - AllegroEsclerosis Múltiple Remitente Recurrente (RRMS)MedDRA version: 9.1Level: PTClassification code 10028245Term: Multiple sclerosis
EUCTR2007-003226-19-ESTeva Pharmaceutical Industries Ltd1,000
进行中(未招募)
不适用
Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad de laquinimod frente a placebo con un diseño doble ciego y con una rama con Interferón ß-1a (Avonex®) como tratamiento de referencia con evaluador ciego - BRAVOEsclerosis Múltiple Remitente Recurrente (RRMS)MedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosis
EUCTR2007-005450-23-ESTeva Pharmaceutical Industries Ltd1,200
进行中(未招募)
1 期
Estudio multinacional, multicéntrico, randomizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia, tolerabilidad y seguridad de Talampanel en pacientes con Esclerosis Lateral Amiotrófica (ELA)A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral Sclerosis (ALS)Esclerosis Lateral Amiotrófica (ELA).Amyotrophic lateral sclerosis (ALS).MedDRA version: 9.1Level: PTClassification code 10052653Term: Amyotrophic lateral sclerosis gene carrier
EUCTR2008-002062-62-ESTeva Pharmaceutical Industries, Ltd